-
Pegmolesatide Injection Approved for Marketing by China NMPA
2023-06-30
Recently, the Category 1 innovative drug Pegmolesatide Injection (Chinese trade name: 圣罗莱) of Jiangsu Hansoh Pharmaceutical Group Company Limited is approved by China NMPA.
-
Iruplinalkib Tablets Approved for Marketing by China NMPA
2023-06-28
Recently, the Category 1 innovative drug Iruplinalkib Tablets (Chinese trade name: 启欣可) of Qilu Pharmaceuticals Co., Ltd is approved by China NMPA.
-
Retagliptin Phosphate Tablets Approved for Marketing by NMPA
2023-06-28
Recently, the Category 1 innovative drug Retagliptin Phosphate Tablets (Chinese trade name: 瑞泽唐) of Jiangsu Hengrui Pharmaceuticals Co., Ltd. is approved by China NMPA.
-
Oteseconazole Capsules Approved for Marketing by China NMPA
2023-06-28
Recently, the Category 1 innovative drug Oteseconazole Capsules of eVENUS PHARMACEUTICAL LABORATORIES INC. is approved by China NMPA.
-
Anaprazole Sodium Enteric-coated Tablets Approved for Marketing by China NMPA
2023-06-25
Recently, the Category 1 innovative drug Anaprazole Sodium Enteric-coated Tablets (Chinese trade name: 安久卫) of Xuanzhu (Beijing) Pharmaceutical Technology Co., Ltd. is approved by China NMPA.
-
Vorolanib Tablets Approved for Marketing by China NMPA
2023-06-08
Recently, the Category 1 innovative drug Vorolanib Tablets (Chinese trade name: 伏美纳) of Betta Pharmaceuticals Co., Ltd is approved by China NMPA.
